. 2014 Feb 17;78(2):353–363. doi: 10.1111/bcp.12349

Table 2.

Treatment effects on prothrombin time

Parameter	Warfarin/rivaroxaban (A)	Warfarin/placebo (B)	Rivaroxaban alone (C)	Test/reference	LS mean ratio (90% CI)
E_max (x-fold)	4.39	1.88	1.57	A/C	2.79 (2.63–2.96)
E_max (x-fold)	4.39	1.88	1.57	A/B	2.33 (2.20–2.47)
E_max,_BA (s)	45.0	11.6	7.3	A/C	6.15 (5.60–6.76)
E_max,_BA (s)	45.0	11.6	7.3	A/B	3.88 (3.53–4.27)
AUC_(0–24) (x-fold h⁻¹)	55.35	37.89	20.41	A/C	2.71 (2.47–2.98)
AUC_(0–24) (x-fold h⁻¹)	55.35	37.89	20.41	A/B	1.46 (1.33–1.60)
AUC_BA(0–24) (s h⁻¹)	413.41	179.94	33.06	A/C	12.51 (10.68–14.64)
AUC_BA(0–24) (s h⁻¹)	413.41	179.94	33.06	A/B	2.30 (1.96–2.69)

Results are geometric means (n = 26–28). Abbreviations are as follows: AUC_(0–24), area under the effect–time curve from time 0 to 24 h; BA, baseline adjusted; CI, confidence interval; E_max, maximal effect; LS, least-squares.